Hypofractionated stereotactic radiotherapy for large arteriovenous malformations

Area of Science:

• Neurology
• Neurosurgery
• Radiation Oncology

Background:

• Cerebral arteriovenous malformations (AVMs) present risks of intracranial hemorrhage.
• Microsurgery, radiosurgery, and embolization are standard treatments, but options for large AVMs are debated.
• Hypofractionated stereotactic radiotherapy (HSRT) is an alternative for complex AVMs.

Purpose of the Study:

• To review literature on HSRT outcomes for large to giant cerebral AVMs.
• To evaluate AVM obliteration rates and complication profiles associated with HSRT.
• To compare HSRT efficacy with other treatment modalities.

Main Methods:

• Literature review of recent studies on HSRT for cerebral AVMs.
• Analysis of AVM obliteration rates and complication data.
• Comparison of HSRT outcomes with stereotactic radiosurgery (SRS) and microsurgery.

Main Results:

• HSRT demonstrated AVM obliteration rates comparable to SRS.
• HSRT effectively reduced AVM size, facilitating further treatment.
• Higher fractional doses correlated with better response but increased complication risk.
• Fractionated regimens (e.g., 7 Gy × 4, 6-6.5 Gy × 5) offer a balance between obliteration and complications.
• Pre-HSRT embolization showed no significant benefit for obliteration or volume reduction.

Conclusions:

• HSRT is a viable primary treatment for large to giant cerebral AVMs.
• Optimizing HSRT fractionation is crucial to balance efficacy and safety.
• Further prospective studies are needed to confirm long-term outcomes.